Cardiolipin Screen ELISA is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human β2-glycoprotein I for the combined quantitative and qualitative detection of IgA, IgG and IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed out of cardiolipin and β2-glycoprotein I which are expressed only when β2-glycoprotein I interacts with cardiolipin. The assay is an aid in the diagnosis and risk estimation of thrombosis in patients with systemic lupus erythematosus (SLE).
Contents of Kit
Sample Buffer (5x): 1 x 20ml Wash Buffer (50x): 1 x 20ml. Negative Control: 1 x 1.5ml Positive Control: 1 x 1.5ml Cut-off Calibrator: 1 x 1.5ml Calibrators: 6 x 1.5ml Conjugate, IgA/G: 1 x 15ml TMB Substrate: 1 x 15ml Stop Solution: 1 x 15ml Microtiter plate: 12 x 8 well strips
Storage
2-8°C
Precision
Detection Range
0 - 300 U/mL, cut-off 20 U/mL
Sensitivity
1.0 U/ml
General Description
Cardiolipin Screen ELISA is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human β2-glycoprotein I for the combined quantitative detection of IgA, IgG and IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed out of cardiolipin and β2-glycoprotein I which are expressed only when β2-glycoprotein I interacts with cardiolipin. The assay is an aid in the diagnosis and risk estimation of thrombosis in patients with systemic lupus erythematosus (SLE). Antibodies against cardiolipin belong to the group of anti-phospholipid antibodies specific for negatively charged phospholipids, components of biological membranes.Cardiolipin is an acidic phospholipid derived from glycerol and was namend because of its isolation from bovine heart in 1941. Anti-phospholipid antibodies are frequently found in sera of patients with systemic lupus erythematosus (SLE) and related diseases. The prevalence of anti-cardiolipin antibodies in SLE is 24-50 %. The occurrence of anti-cardiolipin antibodies in patients with SLE and related diseases is typical for a secondary anti-phospholipid syndrome (APS). In contrast, anti-cardiolipin antibodies in patients with no other autoimmune diseases characterize the primary anti-phospholipide syndrome (APS). Many studies have shown a correlation between these autoantibodies and an enhanced incidence of thrombosis, thrombocytopenia and habitual abortions (as a consequence of placental infarct). The exact mechanism by which pathogenic anti-phospholipid antibodies induce thrombosis is not yet revealed fully.
Standard Curve
Citations
Publication ()
Have you cited DEIABL326 in a publication? Let us know and earn a reward for your research.
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
